Q-omics provides the consensus-scored GAPDHP42 profile across patient tissues and cancer cell-line models. GAPDHP42 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, GAPDHP42 is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, GAPDHP42 RNA expression shows 14,591 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, LUAD, and THYM as cancer lineages where GAPDHP42 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP42 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP42 survival associations across molecular data types. GAPDHP42 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP42 RNA expression–survival associations across cancer types. High GAPDHP42 expression shows unfavorable associations in COAD and KICH, but favorable associations in BLCA, LGG, UCS and SKCM. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for GAPDHP42 RNA expression.
This table summarizes GAPDHP42 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP42. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP42 shows lower tumor expression in LUAD, KICH and BRCA. The LUAD box plot shows higher GAPDHP42 RNA expression in normal versus tumor tissue (log2 FC = −0.167, t-test p = .001).
This table shows molecular features associated with GAPDHP42 in patient tissues and cancer cell lines. In patient samples, GAPDHP42 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
